Reconsidering time from diagnosis to treatment in acute myeloid leukemia: from therapeutic urgency to biologically informed timing
TDT should be viewed as a biology-adapted decision rather than an urgency metric: short, purposeful delays to complete genomic profiling can optimize treatment selection without harming outcomes, whereas system-driven delays remain detrimental and inequitable.
Authors
- Antonino Mulè (ORCID: https://orcid.org/0000-0002-2324-6375)
- Matteo Molica (ORCID: https://orcid.org/0000-0001-6391-4406)
- Marco Rossi (ORCID: https://orcid.org/0000-0002-7258-475X)
- L. De Fazio
- Ferdinando Porretto
- Caterina Alati
- Massimo Martino
Institutions
- Dulbecco Telethon Institute (IT)
- Azienda ospedaliera "Bianchi-Melacrino-Morelli" (IT)
- Ospedale Vincenzo Cervello (IT)
- La Maddalena (IT)
Publication Details
- Journal
- Expert Review of Hematology
- Published
- 2026-03-28
- DOI
- https://doi.org/10.1080/17474086.2026.2653588
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00